

THE CAR T-CELL JOURNEY

1. APHERESIS
2. T-CELL ENRICHMENT
3. T-CELL ACTIVATION
4. GENE TRANSDUCTION
5. T-CELL EXPANSION
6. FORMULATION AND TESTING

Click each stage to find out more

CAR: chimeric antigen receptor

KITE and the KITE Logo are registered trademarks of Kite Pharma, Inc. GILEAD is a registered trademark of Gilead Sciences, Inc. © 2020 Kite Pharma, Inc. All rights reserved.
1. APHERESIS

Mononuclear white blood cells make up the body’s immune response\(^1\). These are collected from the patient’s peripheral blood.\(^2\)

Collected apheresis material may be frozen or otherwise cryopreserved before transportation to the manufacturing facility.\(^2\)

1. Whole blood

2. Plasma

3. Leukocytes

4. Red blood cells

5. Leukocyte removal for further enrichment

---


KITE and the KITE Logo are registered trademarks of Kite Pharma, Inc. GILEAD is a registered trademark of Gilead Sciences, Inc. © 2020 Kite Pharma, Inc. All rights reserved.
2. T-CELL ENRICHMENT

At the manufacturing facility, patient cells undergo an enrichment step that can be accomplished by a variety of methods, such as centrifugation, fractionation, and the use of immunomagnetic beads.\textsuperscript{1,2} Specific cell populations, such as CD4+ and CD8+ T cells, can be further selected.\textsuperscript{2} The method used may also depend on the need to remove circulating tumor cells (blasts) from the sample.\textsuperscript{3,4}

The T cells can be used directly or cryopreserved for future use.\textsuperscript{1}
The enriched T cells must next be activated to increase the efficiency of the transduction process that introduces the CAR into the isolated T cells. This requires sustained and sufficient activation, which can be achieved via different processes, including:

- Cell-based activation using the patient’s dendritic cells, which process the cancer’s antigen and present to T cells for a strong immune response

- Antibody-coated beads that stimulate T cells

- Anti-CD3/CD28 monoclonal antibodies that support T-cell activation in the presence of interleukin-2 (IL-2)
4. GENE TRANSDUCTION

The CAR gene targeting the patient’s cancer cells can be introduced into the activated T cells through different viral approaches:

- Retroviral vectors, which are stable and result in high gene expression
- Lentiviral vectors, which are stable with high gene expression and may be able to support transduction of non-dividing cells

Viral vector containing CAR gene

T cells expressing CAR T receptor
5. T-CELL EXPANSION

The newly made CAR T cells undergo their first expansion \textit{ex vivo}, typically in the presence of growth factors such as IL-2, until sufficient numbers of CAR T cells are obtained.
6. FORMULATION AND TESTING

The CAR T cells are washed, concentrated, formulated to dose, and cryopreserved. Quality tests of the CAR T-cell product assess for:

- Appearance and product identity
- Potency
- Purity

The product is released upon successful completion of all testing and quality assurance checks. The product is then ready for transportation back to the medical center.

Patients receive lymphodepleting chemotherapy to prepare them for CAR T-cell infusion. This allows for expansion and anti-tumor activity of the cells after infusion. After a few days, the CAR T cells are thawed and infused into the patient.